 Two global clinical studies to evaluate NEObodyTM product candidate, ADG116, and SAFEbodyTM product candidate, ADG126, in combination with KEYTRUDA pembrolizumab for patients with advancedmetastatic solid tumors Two global clinical studies to evaluate NEObodyTM product candidate, ADG116, and SAFEbodyTM product candidate, ADG126, in combination with KEYTRUDA pembrolizumab for patients with advancedmetastatic solid tumors 